Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB

Neuroscientific Biopharmaceuticals — Gold Coast Investment Showcase 2021

25 slides from Neuroscientific Biopharmaceuticals's conference presentation, Jun 23, 2021

  1. Slide 1: NeuroScientific presenting at Gold Coast Investment Showcase

    ASX ANNOUNCEMENT 23 JUNE 2021 NEUROSCIENTIFIC PRESENTING AT GOLD COAST For personal use only INVESTMENT SHOWCASE NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) (“NeuroScientific” or “the company”) is pleased to announce that Director of Operations Dr Alexandra Heaton will present at the Gold Coas

  2. Slide 2: About EmtinB preclinical research and Phase I plans

    Our preclinical research has established that EmtinBTM is highly specific and selective for its target receptor, safe and well tolerated at high concentrations, and is able to penetrate the blood brain barrier. A series of Phase I clinical studies will be conducted to establish the safety profile of

  3. Slide 3: Novel Drug Therapies for Neurodegenerative Conditions

    NOVEL DRUG THERAPIES FOR For personal use only NEURODEGENERATIVE CONDITIONS Corporate Update June 2021

  4. Slide 4: Disclaimer

    DISCLAIMER The purpose of the presentation is to provide an update of the business of For personal use only NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further ex

  5. Slide 5: Summary Overview

    SUMMARY OVERVIEW NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD (ASX: NSB) For personal use only  Drug development company with an advanced preclinical lead candidate called EmtinB™; funded through to completion of Phase I ocular and neurology clinical studies  EmtinB™ targets LRP-1 receptors expressed on

  6. Slide 6: Financial Metrics & Milestones

    FINANCIAL METRICS & MILESTONES For personal use only FINANCIALS  ~$14.5M cash on hand  ~$2.0M preclinical R&D costs for FY21  ~$4.5M clinical development cost over next 12 months  Recently appointed Paul Rennie as Non-executive Chairman ASX code NSB  Novel lead drug candidate transitioning to c

  7. Slide 7: EmtinB Development Plan

    EMTINB DEVELOPMENT PLAN For personal use only 2021 2022 Ocular safety studies; up to 4- Ph1 neurology study weeks in primates Q3 2021 Ph2 ocular study Q2 2021 Q3 2022 Completion of preclinical neurology Ph1 ocular study Ph2 neurology study safety studies Q4 2021 Q4 2022 Q3 2021 Q2 2021 Q3 2021 Q4 20

  8. Slide 8: Leadership Team

    LEADERSHIP TEAM For personal use only NSB is pleased to announce the appointment of Paul Rennie as Non-executive Chairman , MBA OPERATIONAL TEAM Paul Rennie, MBM, MSTC Dougal Thring, MPharmMed NON-EXECUTIVE CHAIRMAN EXECUTIVE DIR & CSO VP Clinical Development Founding director of Actinogen Founding

  9. Slide 9: NeuroScientific Biopharmaceuticals Ltd

    NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD For personal use only NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) is developing peptide-based compounds that prevent neurodegeneration and stimulate neuroregeneration NEUROLOGY Alzheimer’s disease, Multiple sclerosis, TARGETED PEPTIDES spinal cord injury

  10. Slide 10: Investment Opportunity

    INVESTMENT OPPORTUNITY For personal use only  First in-class therapeutic for neurodegenerative conditions NOVEL LEAD COMPOUND  Inhibits cell death (apoptosis), induces regeneration, mediates neuroinflammation NOVEL THERAPEUTIC  LRP-1 is a novel therapeutic target for neurodegenerative conditions

  11. Slide 11: EmtinB: LRP-1 Agonist That Promotes Neuronal Survival & Regeneration

    EMTINB™: LRP-1 AGONIST THAT PROMOTES NEURONAL SURVIVAL & REGENERATION For personal use only METALLOTHIONEIN-IIA EMTINB™ TARGET RECEPTOR INTRACELLULAR SIGNALLING P OH ERK K P K K Akt P CREB MTIIA is expressed post damage in EmtinB is modelled on an active LRP-1 receptor is Activation of LRP-1 stimula

  12. Slide 12: EmtinB – Pipeline in a Product

    EMTINB™ – PIPELINE IN A PRODUCT For personal use only INDICATION RESEARCH IND-ENABLING PHASE I PHASE 2 Alzheimer’s disease NEUROLOGY Multiple sclerosis Glaucoma OPHTHALMOLOGY Optic nerve atrophy EXPLORATORY Multiple Currently investigating Emtin peptides in preventing pulmonary fibrosis in indicatio

  13. Slide 13: Neurology

    For personal use only NEUROLOGY

  14. Slide 14: Neurodegenerative Conditions Contribute to Global Burden of Disease

    NEURODEGENERATIVE CONDITIONS SIGNIFICANTLY CONTRIBUTE TO GLOBAL BURDEN OF DISEASE For personal use only DEMENTIA & ALZHEIMER’S MULTIPLE SCLEROSIS DISEASE 50M people globally have dementia 2.5M global prevalence 70% dementias Alzheimer’s disease 20-50y age range of diagnosis Global prevalence driven

  15. Slide 15: EmtinB Promotes Neuronal Survival

    EMTINB™ PROMOTES NEURONAL SURVIVAL Increases in vitro survival of damaged neurons from different regions of CNS For personal use only CORTEX HIPPOCAMPUS HIPPOCAMPUS: ALZHEIMER’S MODEL 10 13

  16. Slide 16: EmtinB Promotes Neuronal Regeneration

    EMTINB™ PROMOTES NEURONAL REGENERATION Increases in vitro axonal regeneration in neurons from different regions of CNS For personal use only CORTEX HIPPOCAMPUS HIPPOCAMPUS: INJURY MODEL SPINAL CORD: INJURY MODEL 11 14

  17. Slide 17: EmtinB Promotes Remyelination in Multiple Sclerosis Model

    EMTINB™ PROMOTES REMYELINATION IN MULTIPLE SCLEROSIS MODEL For personal use only Effect of EmtinB: % Increase in oligodendrocytes MULTIPLE SCLEROSIS MODEL Mature OGCs 875% OPCs 607%  Mature oligodendrocytes produce the myelin sheath that insulates axons of neurons; in MS, the myelin Control 100% sh

  18. Slide 18: EmtinB Slowed Cognitive Decline in Alzheimer's Model

    EMTINB™ SLOWED COGNITIVE DECLINE IN ALZHEIMERS MODEL Significantly slowed progression of AD in gold standard mouse model (APPswe/PS1) For personal use only AD MOUSE MODEL EFFECT ON ASTROGLIOSIS Cognition: treatment for 48 days EmtinB 70% +7 Control 38% +5 0% 50% 100%  Slowed progression of Alzheime

  19. Slide 19: Ophthalmology

    For personal use only OPHTHALMOLOGY

  20. Slide 20: Over 5% of Global Population Suffer Vision Loss Due to Damaged Optic Nerve

    >5% OF GLOBAL POPULATION SUFFER VISION LOSS DUE TO DAMAGED OPTIC NERVE For personal use only GLAUCOMA Vitreous humour OPTIC NEURITIS Optic nerve 76M global prevalence 10M global prevalence 2nd leading cause of blindness 50% MS patients affected Irreversible damage to the optic nerve Leads to partial

  21. Slide 21: Regenerating the Optic Nerve

    REGENERATING THE OPTIC NERVE For personal use only No Treatment RAT TRANSECTION MODEL cut EmtinB precursor compound (MT-II):  Stimulated regeneration of fully-severed optic nerve by up to 1000um (>250% vs non-treated) from 1 dose Treatment  Axonal regeneration was evident well beyond the transecti

  22. Slide 22: EmtinB Ocular Tissue Penetration

    EMTINB™ OCULAR TISSUE PENETRATION PK and tissue distribution studies in rabbits administered EmtinB via intravitreal delivery demonstrated sufficiency of monthly dosing For personal use only Retina: EmtinB labelled with OG488 present in retinal tissue 6-hours 24-hours 6-days Optic nerve: EmtiB label

  23. Slide 23: EmtinB is Neuroprotective in Glaucoma

    EMTINB™ IS NEUROPROTECTIVE IN GLAUCOMA Demonstrated neuroprotection in pig model of IOP glaucoma NFHp Non-treatment NFHp EmtinB For personal use only GLAUCOMA PIG MODEL  Increased intraocular pressure pig model replicates severe human glaucoma pathology; positive results in this model indicate dise

  24. Slide 24: Research Partners

    RESEARCH PARTNERS Partnering with global leaders in contract research For personal use only NEUROLOGY OPHTHALMOLOGY EXPLORATORY MANUFACTURING 22

  25. Slide 25: For More Information

    FOR MORE INFORMATION: For personal use only Matt Liddelow CEO & Managing Director [email protected] www.neuroscientific.com

NeuroScientific Biopharmaceuticals — Gold Coast Investment Showcase 2021 on 6ix